Cancer, Rare Disease Drugs Among New China Approvals
Takeda, Bayer Gain Along with Dompe, Henlius
Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while biosimilars are expected to move into the spotlight.
You may also be interested in...
Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.
The latest mega deals aimed at bringing Chinese innovation to the US have rekindled go-global hopes for a sector badly needing some cheer. But some investors say out-licensing may be the best route and that Chinese biotech must scale back its do-all mentality and focus on what it does best amid a new reality.
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.